154 related articles for article (PubMed ID: 32763899)
1. Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.
Ghione E; Bergsland N; Dwyer MG; Hagemeier J; Jakimovski D; Ramasamy DP; Hojnacki D; Lizarraga AA; Kolb C; Eckert S; Weinstock-Guttman B; Zivadinov R
AJNR Am J Neuroradiol; 2020 Sep; 41(9):1577-1583. PubMed ID: 32763899
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.
Zivadinov R; Bergsland N; Korn JR; Dwyer MG; Khan N; Medin J; Price JC; Weinstock-Guttman B; Silva D;
AJNR Am J Neuroradiol; 2018 Feb; 39(2):289-295. PubMed ID: 29170269
[TBL] [Abstract][Full Text] [Related]
3. Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.
Ghione E; Bergsland N; Dwyer MG; Hagemeier J; Jakimovski D; Paunkoski I; Ramasamy DP; Silva D; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
AJNR Am J Neuroradiol; 2018 Dec; 39(12):2237-2242. PubMed ID: 30467212
[TBL] [Abstract][Full Text] [Related]
4. Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes.
Jakimovski D; Zivadinov R; Bergsland N; Ramasamy DP; Hagemeier J; Genovese AV; Hojnacki D; Weinstock-Guttman B; Dwyer MG
Neuroimage Clin; 2021; 29():102554. PubMed ID: 33472143
[TBL] [Abstract][Full Text] [Related]
5. Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study.
Barnett M; Bergsland N; Weinstock-Guttman B; Butzkueven H; Kalincik T; Desmond P; Gaillard F; van Pesch V; Ozakbas S; Rojas JI; Boz C; Altintas A; Wang C; Dwyer MG; Yang S; Jakimovski D; Kyle K; Ramasamy DP; Zivadinov R
Neuroimage Clin; 2021; 32():102802. PubMed ID: 34469848
[TBL] [Abstract][Full Text] [Related]
6. A validation study of manual atrophy measures in patients with Multiple Sclerosis.
Cappelle S; Pareto D; Tintoré M; Vidal-Jordana A; Alyafeai R; Alberich M; Sastre-Garriga J; Auger C; Montalban X; Rovira À
Neuroradiology; 2020 Aug; 62(8):955-964. PubMed ID: 32246177
[TBL] [Abstract][Full Text] [Related]
7. Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis.
Dwyer MG; Silva D; Bergsland N; Horakova D; Ramasamy D; Durfee J; Vaneckova M; Havrdova E; Zivadinov R
Neuroimage Clin; 2017; 15():769-779. PubMed ID: 28706852
[TBL] [Abstract][Full Text] [Related]
8. A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.
Zivadinov R; Horakova D; Bergsland N; Hagemeier J; Ramasamy DP; Uher T; Vaneckova M; Havrdova E; Dwyer MG
AJNR Am J Neuroradiol; 2019 Mar; 40(3):446-452. PubMed ID: 30819766
[TBL] [Abstract][Full Text] [Related]
9. Aging and Brain Atrophy in Multiple Sclerosis.
Ghione E; Bergsland N; Dwyer MG; Hagemeier J; Jakimovski D; Paunkoski I; Ramasamy DP; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
J Neuroimaging; 2019 Jul; 29(4):527-535. PubMed ID: 31074192
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
Zivadinov R; Medin J; Khan N; Korn JR; Bergsland N; Dwyer MG; Chitnis T; Naismith RT; Alvarez E; Kinkel P; Cohan S; Hunter SF; Silva D; Weinstock-Guttman B;
J Neuroimaging; 2018 Jul; 28(4):399-405. PubMed ID: 29749661
[TBL] [Abstract][Full Text] [Related]
11. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study.
Jacobsen C; Hagemeier J; Myhr KM; Nyland H; Lode K; Bergsland N; Ramasamy DP; Dalaker TO; Larsen JP; Farbu E; Zivadinov R
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1109-15. PubMed ID: 24554101
[TBL] [Abstract][Full Text] [Related]
12. Late onset multiple sclerosis is associated with more severe ventricle expansion.
Jakimovski D; Dujmic D; Hagemeier J; Ramasamy DP; Bergsland N; Dwyer MG; Eckert S; Kolb C; Lizarraga A; Hojnacki D; Weinstock-Guttman B; Zivadinov R
Mult Scler Relat Disord; 2020 Nov; 46():102588. PubMed ID: 33296984
[TBL] [Abstract][Full Text] [Related]
13. A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.
Uher T; Krasensky J; Vaneckova M; Sobisek L; Seidl Z; Havrdova E; Bergsland N; Dwyer MG; Horakova D; Zivadinov R
J Neuroimaging; 2017 Nov; 27(6):620-629. PubMed ID: 28464417
[TBL] [Abstract][Full Text] [Related]
14. 2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis.
Pontillo G; Cocozza S; Di Stasi M; Carotenuto A; Paolella C; Cipullo MB; Perillo T; Vola EA; Russo C; Masullo M; Moccia M; Lanzillo R; Tedeschi E; Elefante A; Brescia Morra V; Brunetti A; Quarantelli M; Petracca M
Eur Radiol; 2020 Jul; 30(7):3813-3822. PubMed ID: 32100089
[TBL] [Abstract][Full Text] [Related]
15. Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
Sastre-Garriga J; Tur C; Pareto D; Vidal-Jordana A; Auger C; Río J; Huerga E; Tintoré M; Rovira A; Montalban X
Mult Scler; 2015 May; 21(6):749-56. PubMed ID: 25392330
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
[TBL] [Abstract][Full Text] [Related]
17. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.
Eisele P; Szabo K; Ebert A; Platten M; Gass A
J Neuroimaging; 2019 Mar; 29(2):190-192. PubMed ID: 30485572
[TBL] [Abstract][Full Text] [Related]
18. Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis.
Fritz DA; Dwyer MG; Bagnato F; Watts KL; Bratina A; Zorzon M; Durastanti V; Locatelli L; Millefiorini E; Zivadinov R
Neurol Res; 2006 Apr; 28(3):275-9. PubMed ID: 16687053
[TBL] [Abstract][Full Text] [Related]
19. Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.
Ruberte E; Sinnecker T; Amann M; Gaetano L; Naegelin Y; Penner IK; Kuhle J; Derfuss T; Kappos L; Granziera C; Wuerfel J; Yaldizli Ö
Eur Neurol; 2018; 80(3-4):207-214. PubMed ID: 30605898
[TBL] [Abstract][Full Text] [Related]
20. Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis.
Jakimovski D; Zivadinov R; Bergsland N; Ramasamy DP; Hagemeier J; Weinstock-Guttman B; Kolb C; Hojnacki D; Dwyer MG
J Neuroimaging; 2020 May; 30(3):342-350. PubMed ID: 32392376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
